World Vape Day 2025 Marks 20 Years of Tobacco Harm Reduction Progress
World Vape Day 2025
BRUSSELS, May 30, 2025 (GLOBE NEWSWIRE) -- Today, the global vaping community celebrates World Vape Day 2025, highlighting two decades of innovation and scientific advancement in tobacco harm reduction. This year's theme, '20 Years of Facts', underscores the growing body of evidence supporting vaping as a less harmful alternative to smoking and its role in helping millions of adults quit combustible tobacco.
World Vape Day is celebrated one day before World No Tobacco Day, emphasising the importance of evidence-based harm reduction tools in the fight against smoking-related disease. Since the introduction of modern vaping devices in 2003 and their subsequent arrival and uptake in Europe and the US, vaping has become a cornerstone of smoking cessation worldwide.
Countries such as Sweden, the UK, and New Zealand, which have embraced tobacco harm reduction policies and ensured access to regulated vaping products, now report record-low smoking rates. Sweden, for example, is poised to become the first smoke-free country in Europe, defined as having fewer than 5% daily smokers—an achievement attributed to widespread acceptance of safer nicotine alternatives. In contrast, nations with restrictive policies continue to lag behind in reducing smoking prevalence.
Despite robust scientific consensus, misinformation and regulatory barriers persist. Many health advocates warn that bans and flavour restrictions risk reversing progress by pushing former smokers back to cigarettes. 'Persistent misperceptions about the relative risks of vaping versus smoking remain a significant challenge, with studies showing that a majority of smokers in many countries still believe vaping is as harmful or more harmful than smoking,' commented Michael Landl, Director of the World Vapers' Alliance.
World Vape Day is a reminder for policymakers, public health officials, and the media to prioritise facts over fear and to recognise the real-world impact and potentials of harm reduction. Advocates stress that an inclusive, evidence-based approach is essential to accelerate progress towards global smoke-free goals and to ensure that adult smokers have access to effective alternatives.
For more information, campaign resources, and a full list of 20 facts about vaping and harm reduction, visit https://worldvapersalliance.com/world-vape-day/.
Media Contact: Michael Landl World Vapers' Alliance info@worldvapersalliance.comworldvapersalliance.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c5dd147-1785-4bb0-8249-4ab534f51783Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@
Business Upturn
an hour ago
- Business Upturn
American Botanical Council Acquires Full Rights to Steven Foster Photo Library
Austin, Texas, June 06, 2025 (GLOBE NEWSWIRE) — The nonprofit American Botanical Council (ABC) announces that it has obtained ownership rights to the entire collection of medicinal and aromatic plant photographs taken by the late botanist, author, and preeminent photographer Steven Foster (1957–2022). Foster was well-known and widely respected as the author or co-author of 21 books on herbs and medicinal plants. He also wrote more than 800 articles and reviews on herbal medicine, ethnobotany, sustainable sourcing, conservation, and related subjects, including more than 100 articles and reviews in ABC's peer-reviewed journal HerbalGram. His extensive photographic library includes more than 150,000 images of more than 1,700 accurately identified medicinal and aromatic plant species. This includes Foster's photos of many native American medicinal plants, as well as other plants he encountered during his travels in countries around the world, including Argentina, Armenia, Belize, China, Costa Rica, Egypt, England, Georgia, Germany, Guatemala, Japan, Montenegro, the Netherlands, Peru, Switzerland, Trinidad and Tobago, Vietnam, and elsewhere. Foster was a member of ABC's Board of Trustees for more than 20 years and president for 10 years. He provided frequent and instrumental support for HerbalGram and served as a contributing editor, peer reviewer, and author of dozens of feature-length articles. He also contributed hundreds of medicinal plant photos from his extensive library, including at least 60 photos that appeared on the magazine's cover. His photography filled nearly every issue of HerbalGram since issue 24 in 1991. After Foster's untimely death in January 2022, ABC continued to have access to and permission to use his photos in a variety of ABC publications and communications through a special arrangement with his estate. ABC continued to feature his photos on ABC's website, in publications of the ABC-AHP-NCNPR Botanical Adulterants Prevention Program (BAPP), and in HerbalGram , ABC's monthly newsletter HerbalEGram, ABC's weekly newsletter Herbal News & Events, and other ABC publications. Now, ABC has finalized the purchase of Foster's entire digital photo library, including full rights to all of the images. Credits to Foster's photographs will now read: 'Photo by Steven Foster ©2025 ABC.' 'For more than 40 years, Steven was a close personal friend and colleague and a primary contributor to ABC's nonprofit research and educational mission, publications, and programs,' said ABC Founder and Executive Director Mark Blumenthal. 'Steven's intelligence, botanical knowledge, insightful and deeply informed writing, and his compelling photography were an integral part of the development and evolution of HerbalGram and ABC. 'It has been ABC's goal not only to provide authoritative, reliable, science-based information on herbs and medicinal plants, but also to show the beauty of these plants, which we have done for decades thanks in large part to Steven's incredibly beautiful photos,' Blumenthal added. 'Now, ABC has the opportunity to continue its nonprofit educational mission with Steven's photos and to help expand the herb community and general public's awareness of and appreciation for Steven's remarkable photographic legacy. ABC Art Director Matt Magruder said: 'Securing the ownership of Steven Foster's photography library is an exciting new chapter for HerbalGram and all of ABC's various programs and publications. Steven's photography has been a foundational — and visually stunning — part of the organization from early on. As a fellow photographer, I am grateful to be able to honor Steven and to continue to share his quintessential photographic legacy through ABC's stewardship moving forward.' Michael J. Balick, PhD, member of ABC's Board of Trustees and vice president for botanical science, director and senior philecology curator of the Institute of Economic Botany at the New York Botanical Garden, said: 'I was delighted to learn that ABC has acquired the Steven Foster Photo Library. Steven's 'plant's eye view' was nothing short of extraordinary, and this is reflected in all of the artistic and scientific work that he did over so many decades. He was enthusiastic and generous about sharing his talents as a photographer and providing his guidance to anyone who asked for his advice, regardless of their level of botanical sophistication. When I invited him to illustrate the third edition of the Handbook of Poisonous and Injurious Plants [Springer, 2017], he provided his best work, and the photos that grace the pages of this reference book are not only useful for identification in cases of suspected poisoning, but also works of beautifully composed botanical art. We all miss Steven, who left us prematurely, and I am grateful to ABC and its donors for ensuring that this part of his legacy will endure, educating and captivating us all for many more decades.' Blumenthal noted that, at a time when people are beginning to use artificial intelligence as a source for botanical images, one primary benefit of Foster's photographs is the reliable and accurate identification of the depicted plant species. As an expert botanist, Foster properly identified the botanicals in his photos. Aside from the beauty of the photos, this benefit is a key feature of ABC's Steven Foster Photo Library. ABC featured a memorial tribute to Steven Foster in HerbalGram issue 133 and a pictorial of some of his medicinal plant photography in issue 134. A new pictorial of Foster's brilliant medicinal plant photos was just published in the current issue of HerbalGram , issue 143. In addition, ABC has named its newest award for botanical excellence after Foster, the ABC Steven Foster Excellence in Botanical Conservation and Sustainability Award, which is announced each spring at the annual ABC Celebration at Natural Products Expo West in Anaheim. Attachments Echinacea Purpurea Passiflora Incarnata Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
an hour ago
- Business Upturn
First Ascent Biomedical and Fight Colorectal Cancer Announce Groundbreaking Study to Advance Precision Oncology for Colorectal Cancer Patients
By GlobeNewswire Published on June 6, 2025, 23:41 IST Springfield, Mo., June 06, 2025 (GLOBE NEWSWIRE) — First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to announce a new collaboration with national nonprofit Fight Colorectal Cancer (Fight CRC) to launch a prospective feasibility study aimed at transforming colorectal cancer treatment. Funded by a $350,000 grant from Fight CRC, and spearheaded by Anjee Davis, chief executive officer, this innovative study will leverage First Ascent's cutting-edge xDRIVE tumor profiling technology to deliver rapid, personalized treatment insights for patients fighting colon cancer in Minnesota. 'Fight CRC is committed to empowering patients through innovation,' said Davis. 'This grant underscores our strategic focus on enhancing care through advanced research, particularly for those with limited treatment options.' The study, set to begin enrollment in April or May 2025, will focus on 25 patients with metastatic colorectal cancer. By integrating functional drug testing, genetic analysis, and artificial intelligence, First Ascent's xDRIVE platform will provide oncologists with detailed tumor profiling data and tailored treatment options, aiming to enhance patient outcomes. Leading the clinical efforts are Hao Xie, MD, PhD, a gastrointestinal cancer specialist and precision medicine expert, and Dr. Boardman, whose work in cancer genetics and early detection has advanced the field of colorectal cancer care. Noah Berlow, PhD, First Ascent's Chief Technology Officer and the study's principal investigator, brings his expertise in AI-driven cancer research to oversee the project. Together, this team is poised to demonstrate the power of rapid, individualized tumor profiling to better understand each patient's unique cancer. 'This collaboration with Fight Colorectal Cancer is another important step in transforming how we approach cancer treatment,' said Jim Foote, founder and chief executive officer, First Ascent Biomedical. 'We are honored to be part of this effort.' The study is expected to complete enrollment within nine months and will provide actionable data to oncologists for patients requiring advanced treatment options. Patients interested in participating must be seen in Rochester, MN. Information will soon be available on Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
